Generic Name and Formulations:
Dinoprostone 0.5mg/3g; endocervical gel.
Indications for PREPIDIL:
Ripening an unfavorable cervix in pregnant women at or near term.
See full labeling.
Where oxytocics or prolonged uterine contractions are inappropriate, including: history of cesarean section, major uterine surgery, presence of cephalopelvic disproportion, difficult labor, traumatic delivery, 6 or more previous term pregnancies, nonvertex presentation, hyperactive or hypertonic uterine patterns, fetal distress where delivery is not imminent. Ruptured membranes. Placenta previa or unexplained vaginal bleeding. When vaginal delivery is not indicated. Concomitant oxytocics.
For hospital use only when immediate intensive care and acute surgical facilities can be provided. Avoid contact with skin. Monitor uterine activity, fetal status, cervix. History of/or asthma. Glaucoma or increased intraocular pressure. If hypersensitivity reaction is suspected, remove Prepidil gel if possible. Renal or hepatic dysfunction. Pregnancy (Cat.C).
Potentiates oxytocics. Oxytocin: a dosing interval of 6–12hrs is needed, if used following Prepidil administration.
Maternal: Uterine rupture, uterine contraction abnormality, GI upset, back pain, warm feeling in vagina, fever, premature rupture of membranes. Fetal: Heart rate abnormality, fetal depression, fetal acidosis. Amnionitis and intrauterine fetal sepsis associated with extra-intrauterine administration.
Prefilled-syringe applicator (w. catheters)—5
Neurology Advisor Articles
- OCD in Duchenne Muscular Dystrophy Features Distinct Phenotype, Associated Symptoms
- History of Migraine Associated With Higher Risk for Cochlear Disorders
- Patent Foramen Ovale Closure for Stroke Prevention: Key Principles for Clinical Practice
- Vagus Nerve Stimulation in Pediatric Epilepsy: Weighing the Risks and Benefits
- A Model for Predicting Quality of Life Improvements After Deep Brain Stimulation
- Some Statins May Be Associated With Cognition, Memory Deficits
- Neuropathic Pain Treatments
- Cannabis for Multiple Sclerosis: Prescriber's Perspective
- New Monoclonal Antibody BAN2401 Reduces Amyloid Plaques, Improves Cognition in Alzheimer's
- Nonpharmacologic Interventions for Alzheimer's Have Greater Impact on Outcomes Than Currently Available Medications
- Population-Based Incidence of Acute Idiopathic Optic Neuritis Estimated
- First-in-Class Therapy Approved for Polyneuropathy Caused by hATTR
- High Anxiety Symptoms Prevalent in Epilepsy, Mesial Temporal Sclerosis
- Advance Care Planning Doesn't Aid Quality of Life
- Variation in Specialty Drug Coverage Across Health Plans